Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC

NCT ID: NCT01290783

Last Updated: 2015-04-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 390 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2015-12-31

Brief Summary

Trial design:

• Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen.
• Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
• Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria, Poland, Serbia, Russia, Ukraine and the United Kingdom).
• Dosing regimen:

• Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan and HA-Irinotecan dose in must be reduced to 150 mg/m2).
• Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
• 5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
• Repeat every 2 weeks for 8 months.
• Patient accrual over approximately 12-14 months.
• Monitoring to 18 months post-randomization.
• 390 patients.
• Progression Free Survival (PFS) primary endpoint.
• Safety analysis on the initial 20 patients.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

FOLFIRI

Group Type: ACTIVE_COMPARATOR

Irintoecan

Intervention Type: DRUG

• Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
• Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
• 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
• Repeat every two weeks.
• 8 months of treatment.

FOLF(HA)iri

Group Type: EXPERIMENTAL

HA-Irinotecan solution for Infusion

Intervention Type: DRUG

• HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
• Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
• 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
• Repeat every two weeks
• 8 months of treatment.

Interventions

Irintoecan

• Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
• Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
• 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
• Repeat every two weeks.
• 8 months of treatment.

Intervention Type: DRUG

HA-Irinotecan solution for Infusion

• HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
• Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
• 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
• Repeat every two weeks
• 8 months of treatment.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Metastatic colorectal cancer with disease progression after first or second line chemotherapy
• Irinotecan naïve.
• ECOG performance status of 0 or 1.
• Measurable disease, i.e. at least one measurable metastatic lesion (spiral CT or MRI).
• Histological proof of colorectal cancer.
• 18 years of age and older.
• Adequately recovered from and at least 4 weeks after recent surgery or chemotherapy.
• Women of child-bearing potential (WOCBP) and male partners of WOCBP must agree to use adequate contraception.
• Patient consent obtained and signed according to local and/or national ethics.
• CT or MRI scan of chest/abdomen/pelvis within 21 days prior to randomization.
• Hematology done within 14 days prior to randomization.
• Chemistry done within 14 days prior to randomization.

Exclusion Criteria

• History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 5 years.
• Locally advanced or recurrent disease only.
• Unsuitability for irinotecan including known Gilbert's syndrome, active inflammatory bowel disease or chronic diarrhea greater than or equal to grade 2.
• Abdominal or pelvic radiation therapy within the last 12 months.
• Women who are pregnant or breastfeeding.
• Any condition (e.g., psychological, geographical) that would render the protocol treatment dangerous.
• Significant cardiac disease.
• Untreated or symptomatic brain or central nervous system (CNS).
• Presence of pleural effusion or ascites requiring therapeutic thoracocentesis or paracentesis.
• Current partial or complete bowel obstruction.
• Concomitant active infection.
• Enrolled in any other investigational trial, unless treatment in that trial has been discontinued at least 30 days prior to signing the Informed Consent for the ACO-002 study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alchemia Oncology

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter Gibbs, MD

Role: PRINCIPAL_INVESTIGATOR

Melbourne Health

Locations

Southern Medical Day Care Centre

Wollongong, New South Wales, Australia

Western General Hospital

Melbourne, Victoria, Australia

Royal Melbourne Hospital

Melbourne, Victoria, Australia

Monash Medical Centre

Melbourne, Victoria, Australia

Border Medical Oncology

Wodonga, Victoria, Australia

Countries

Australia

References

Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, Underhill CR, Fox RM, Clavant SP, Leung J, Pho M, Brown TJ. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011 Jan;67(1):153-63. doi: 10.1007/s00280-010-1303-3. Epub 2010 Mar 24.

Reference Type: BACKGROUND

PMID: 20333384 (View on PubMed)

Other Identifiers

ACO-002

Identifier Type: -

Identifier Source: org_study_id